US2012134989A1PendingUtilityA1
Antibody formulations
Est. expiryJun 14, 2027(~0.9 yrs left)· nominal 20-yr term from priority
Inventors:Kevin Maloney
A61P 37/02A61P 3/10A61P 35/00A61P 25/00A61P 29/00A61P 11/06A61P 21/00A61P 1/04A61P 1/00A61P 19/02A61P 17/00A61K 39/39591C07K 2317/24A61K 9/0019A61K 47/183A61K 47/02C07K 16/2839A61K 47/26
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Formulations of VLA-4 binding antibody are described.
Claims
exact text as granted — not AI-modified1 .- 34 . (canceled)
35 . An aqueous pharmaceutical composition comprising natalizumab at a concentration of 120 mg/mL to 190 mg/mL, sodium phosphate buffer at 5 mM to 15 mM; sodium chloride at 130 mM to 150 mM, polysorbate 80 at 0.02% to 0.08% and having pH 6±0.5.
36 . The composition of claim 35 , wherein the composition comprises 10 mM sodium phosphate buffer.
37 . The composition of claim 35 , wherein the composition comprises 140 mM sodium chloride.
38 . The composition of claim 35 , wherein the composition comprises 0.04% (w/v) polysorbate 80.
39 . The composition of claim 35 , wherein the composition comprises 0.02% (w/v) polysorbate 80.
40 . The composition of claim 35 , wherein the composition comprises 10 mM sodium phosphate buffer, 140 mM sodium chloride, 0.04% polysorbate 80 and wherein the composition is at pH 6.0±0.5.
41 . The composition of claim 35 , wherein the composition comprises 10 mM sodium phosphate buffer, 140 mM sodium chloride, 0.02% polysorbate 80 and wherein the composition is at pH 6.0±0.5.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.